Cardiol Therapeutics Inc.
CRDL.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 11.45% | 22.48% | -25.36% | 15.19% | -4.08% |
| Total Depreciation and Amortization | -46.24% | -87.38% | -59.29% | -61.93% | -29.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 68.34% | -51.55% | 216.37% | -46.81% | 447.11% |
| Change in Net Operating Assets | -163.94% | 76.95% | -15.10% | -360.00% | -37.43% |
| Cash from Operations | 6.20% | 11.73% | 5.76% | 2.93% | 15.91% |
| Capital Expenditure | 50.00% | 62.07% | -67.86% | -219.23% | 44.30% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 50.00% | 62.07% | -67.86% | -219.23% | 44.30% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -200.00% | -50.00% | 0.00% | 0.00% |
| Issuance of Common Stock | -24.90% | -- | -60.71% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 82.01% | -- | -- | -- | -- |
| Cash from Financing | -16.48% | -197.06% | -74.08% | -116.96% | 131,001.96% |
| Foreign Exchange rate Adjustments | -132.83% | 203.12% | -470.66% | -120.61% | 76.96% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -33.08% | 20.00% | -10.76% | -7.66% | 354.66% |